AbbVie plays it cool in the face of Humira biosimi

AbbVie plays it cool in the face of Humira biosimilars – FiercePharma https://t.co/Ucbli32yrk

Join the Crohn’s & Colitis Public Informatio

Join the Crohn’s & Colitis Public Information Event

📅 21 March 2023
🕒 5.30pm – 7.30pm
📍 Lecture Theatre 1, John… https://t.co/PgODevAU3k

I back @CrohnsColitisUK’s call for early diagnosis. We need urgent action to reduce the burden of Crohn’s and Colit… https://t.co/aJzMEjy5t3

We had the pleasure of welcoming Bryony Mathew, the British Ambassador to Iceland, at Alvotech last month. The team… https://t.co/8d9ppltBT0

Is it getting easier or more challenging for you to get an appointment to discuss your #Crohns / #Colitis / #IBD ??

Hooked up for the first infusion of the year and feeling grateful. Love coming to see the nurses who do such a fant… https://t.co/tRTJy4YOWC

Prof. Khalid Alnaqbi, Consultant Rheumatologist, Tawam Hospital, presented a study on Consensus Recommendations on… https://t.co/HkL9yzrtix

When a product comes off patent, the price doesn’t always drop and it doesn’t always become more widely available.… https://t.co/Bt70FhdFXK

@lauraandreoli80 @KDAO2011 @MotherToBaby I’d no concerns about the safety of biosimilars compared to parent drug. S… https://t.co/Qa6C9Zd3cq

@pierre_niles @EugeneB08701074 @PeteAguilar 2
PRICE shld be $78-$138/person/YEAR!
Researchers @ Imperial College Lo… https://t.co/3YdoarXjkl